Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTC518 in Huntington's disease
ISRCTN97180769Phase 2Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Jun 2022
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of votoplam in Huntington disease (HD) (12 arms), sponsored by PTC Therapeutics, Inc. Primary endpoints: Number of participants with adverse events and Change from baseline in blood total huntingtin protein at Month 3. Started Jun 2022; status: completed.
02
Drugs
votoplam
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on ISRCTN97180769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN97180769.